• 1
    Richardson PG,Sonneveld P,Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 24872498.
  • 2
    Richardson P,Sonneveld P,Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial [abstract]. Blood. 2005; 106: 715a. Abstract 2547.
  • 3
    Richardson PG,Sonneveld P,Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110: 35573560.
  • 4
    Adams J,Palombella VJ,Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 26152622.
  • 5
    Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003; 426: 895899.
  • 6
    Orlowski RZ,Stinchcombe TE,Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20: 44204427.
  • 7
    Richardson PG,Barlogie B,Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 26092617.
  • 8
    Papandreou CN,Daliani DD,Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 21082121.
  • 9
    deVos S,Dakhil S,McLaughlin P, et al. Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study [abstract]. Blood. 2005; 106: 10a. Abstract 17.
  • 10
    Durie BG,Harousseau JL,Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 14671473.
  • 11
    Kaplan EL,Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 12
    Mateos MV,Hernandez JM,Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006; 108: 21652172.
  • 13
    Popat R,Oakervee HE,Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood. 2005; 106: 717a. Abstract 2554.
  • 14
    Wang M,Delasalle K,Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood. 2005; 106: 231a. Abstract 784.
  • 15
    Harousseau JL,Marit G,Caillot D, et al. VELCADE/dexamethasone (Val/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an interim analysis of the IFM 2005-01 randomized multicenter phase III trial [abstract]. Blood. 2006; 108: 21a. Abstract 56.
  • 16
    Popat R,Oakervee H,Curry N, et al. Long-term follow-up of PAD for untreated multiple myeloma [abstract]. Haematologica. 2007; 92: 725.
  • 17
    Kaufman JL,Gleason C,Heffner LT, et al. Bortezomib, thalidomide and dexamethasone as induction [abstract]. Haematologica. 2007; 92: 722.
  • 18
    Suvannasankha A,Smith GG,Juliar BE,Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006; 7: 131134.
  • 19
    DeVos S,Dakhil SR,McLaughlin P, et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular or marginal zone lymphoma: final results [abstract]. Blood. 2006; 108( suppl): 208a. Abstract 694.
  • 20
    O'Connor O,Hamlin P,Moskowitz C, et al. Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma [abstract]. J Clin Oncol. 2007; 25( suppl): 453s. Abstract 8051.
  • 21
    O'Connor OA,Wright J,Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005; 23: 676684.